CTSO ▼ -2.9% - Cytosorbents Corporation $CTSO - CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings CytoSorbents announced new real-world data showing its CytoSorb device significantly reduced severe bleeding in coronary artery bypass graft patients taking ticagrelor, while also providing updates on DrugSorb-ATR pre-submission meetings with the FDA. Despite the positive clinical data, the stock declined 2.9% today, suggesting investors may have been disappointed by the timing of the announcement, the specifics of the data, or broader market conditions. 02-SEP-2026 07:30 AM ET